Durvalumab: all 557 studies that test it

Page 2 of 6. Open to participants first (117), then studies with results posted, then the rest; newest registration first within each.

• Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung CancerRecruitingNCT04499053Phase 2
• Efficacy and Safety of CRT, Durvalumab and Surgery for SSTNot yet recruitingNCT04465968Phase 3
• Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( Dulect2020-1 )RecruitingNCT04443322Not applicable
• Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular CarcinomaRecruitingNCT04430452Phase 2
• AZD6738 Plus Durvalumab in Biliary Tract CancerRecruitingNCT04298008Phase 2
• Phase-II Trial of Induction Chemotherapy and Chemoradiotherapy Plus/Minus Durvalumab and Consolidation Immunotherapy in Patients With Resectable Stage III NSCLC.RecruitingNCT04202809Phase 2
• DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancErRecruitingNCT04106115Phase 1/2
• Capecitabine Plus Concomitant Radiation Therapy Followed by Durvalumab as Preoperative Treatment in Rectal CancerRecruitingNCT04083365Phase 2
• Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver CancerRecruitingNCT03942328Phase 1/2
• Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCCRecruitingNCT03899428Phase 2
• Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor MalignanciesRecruitingNCT03772561Phase 1
• PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast CancerRecruitingNCT03740893Phase 2
• Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLCRecruitingNCT03694236Phase 1/2
• Renal Adjuvant MultiPle Arm Randomised TrialRecruitingNCT03288532Phase 3
• The Drug Rediscovery Protocol (DRUP Trial)RecruitingNCT02925234Phase 2
• Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatmentRecruitingNCT02029001Phase 2
• I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingNCT01042379Phase 2
• A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid TumorsCompletedNCT05712356Phase 2Results posted
• Regorafenib and Durvalumab for the Treatment of High-Risk Liver CancerActive, not recruitingNCT05194293Phase 2Results posted
• A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 InhibitionActive, not recruitingNCT05061134Phase 2Results posted
• Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver TransplantTerminatedNCT05027425Phase 2Results posted
• Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid TumoursActive, not recruitingNCT04999969Phase 2Results posted
• A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Cell Lung CancerTerminatedNCT04951115Phase 2Results posted
• Hepatic Artery Infusion Chemotherapy (HAIC) Plus Durvalumab for Advanced Hepatocellular CarcinomaCompletedNCT04945720Phase 2Results posted
• A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung CancerTerminatedNCT04866017Phase 3Results posted
• Durvalumab and Stereotactic Radiotherapy for Advanced NSCLCTerminatedNCT04786093Phase 2Results posted
• Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung CancerCompletedNCT04774380Phase 3Results posted
• Study of AZD2811 + Durvalumab in ES-SCLCActive, not recruitingNCT04745689Phase 2Results posted
• Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic AgentsActive, not recruitingNCT04739800Phase 2Results posted
• Durvalumab Plus Chemotherapy in Untreated Patients With Extensive-Stage Small Cell Lung CancerCompletedNCT04712903Phase 3Results posted
• Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.CompletedNCT04642469Phase 3Results posted
• Trying to Find the Correct Length of Treatment With Immune Checkpoint TherapyActive, not recruitingNCT04637594Phase 3Results posted
• Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine TumorsTerminatedNCT04538378Phase 2Results posted
• Durvalumab Plus Chemotherapy in ES-SCLC (Oriental)CompletedNCT04449861Phase 3Results posted
• Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLCTerminatedNCT04441138Phase 2Results posted
• Study to Access Safety of Durvalumab in Indian Adult Patients With Locally Advanced NSCLCCompletedNCT04416633Phase 4Results posted
• Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)CompletedNCT04385368Phase 3Results posted
• ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-ImmunotherapyTerminatedNCT04372927Phase 2Results posted
• Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung CancerTerminatedNCT04364048Phase 2Results posted
• Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung CancerTerminatedNCT04348292Phase 1Results posted
• Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen LoadTerminatedNCT04336943Phase 2Results posted
• DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural MesotheliomaCompletedNCT04334759Phase 3Results posted
• Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial CarcinomaTerminatedNCT04322643Phase 2Results posted
• Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic CholangiocarcinomaCompletedNCT04301778Phase 2Results posted
• Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial CancerActive, not recruitingNCT04269200Phase 3Results posted
• Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for ChemotherapyCompletedNCT04249362Phase 2Results posted
• CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast CancerActive, not recruitingNCT04176848Phase 2Results posted
• Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLCTerminatedNCT04163432Phase 2Results posted
• Durvalumab Long-Term Safety and Efficacy StudyCompletedNCT04078152Phase 4Results posted
• CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung CancerActive, not recruitingNCT04062708Phase 2Results posted
• A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by SurgeryCompletedNCT04026412Phase 3Results posted
• AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerTerminatedNCT04019288Phase 1/2Results posted
• Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung CancerCompletedNCT04003246Phase 2Results posted
• Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung CancerCompletedNCT03916419Phase 2Results posted
• Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)Active, not recruitingNCT03875235Phase 3Results posted
• Aromatase Inhibitor and Durvalumab in Postmenopausal Breast CancerTerminatedNCT03874325Phase 2Results posted
• Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected MutationsActive, not recruitingNCT03842228Phase 1Results posted
• Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)CompletedNCT03830866Phase 3Results posted
• Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLCCompletedNCT03822351Phase 2Results posted
• Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast CancerActive, not recruitingNCT03820141Phase 2Results posted
• A Study of Olaparib and Durvalumab in Prostate CancerTerminatedNCT03810105Phase 2Results posted
• AMTEC IIT: Phase 2 Multiarm Study in TNBCTerminatedNCT03801369Phase 2Results posted
• Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY TrialTerminatedNCT03753919Phase 2Results posted
• Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer PatientsActive, not recruitingNCT03737643Phase 3Results posted
• Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBCActive, not recruitingNCT03732677Phase 3Results posted
• A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer PatientsActive, not recruitingNCT03706690Phase 3Results posted
• Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation TherapyActive, not recruitingNCT03703297Phase 3Results posted
• Durvalumab Plus Tremelimumab With Concurrent Radiotherapy for Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation ApproachCompletedNCT03702179Phase 2Results posted
• A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung CancerCompletedNCT03693300Phase 2Results posted
• Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaCompletedNCT03691714Phase 2Results posted
• Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular LymphomaTerminatedNCT03685344Phase 1Results posted
• Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib AloneActive, not recruitingNCT03660826Phase 2Results posted
• CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and TremelimumabCompletedNCT03638141Phase 2Results posted
• MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.CompletedNCT03611556Phase 1/2Results posted
• Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung CancerCompletedNCT03581487Phase 1/2Results posted
• Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHNCompletedNCT03529422Phase 2Results posted
• Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaTerminatedNCT03522584Phase 1/2Results posted
• Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung CancerCompletedNCT03519971Phase 3Results posted
• Durvalumab and "Booster" Radiation in Metastatic Adenocarcinoma of the PancreasTerminatedNCT03490760Phase 2Results posted
• DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated CancersTerminatedNCT03439085Phase 2Results posted
• Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal CancerCompletedNCT03435107Phase 2Results posted
• Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon CancerCompletedNCT03428126Phase 2Results posted
• Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung CancerCompletedNCT03373760Phase 2Results posted
• Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing TherapyActive, not recruitingNCT03334617Phase 2Results posted
• Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced MalignanciesTerminatedNCT03323398Phase 1/2Results posted
• Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular CarcinomaActive, not recruitingNCT03298451Phase 3Results posted
• Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)CompletedNCT03258593Phase 1Results posted
• Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take CisplatinCompletedNCT03258554Phase 2/3Results posted
• RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid CancersActive, not recruitingNCT03215095Early Phase 1Results posted
• Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate CancerCompletedNCT03204812Phase 2Results posted
• Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care TherapyTerminatedNCT03199040Phase 1Results posted
• Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).Active, not recruitingNCT03164616Phase 3Results posted
• Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck CancerCompletedNCT03162224Phase 1/2Results posted
• Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLCActive, not recruitingNCT03141359Phase 2Results posted
• Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast CancerCompletedNCT03132467Early Phase 1Results posted
• Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung OriginCompletedNCT03095274Phase 2Results posted
• Durvalumab in HIV-1 Patients With Solid TumorsCompletedNCT03094286Phase 2Results posted
• An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.CompletedNCT03084471Phase 3Results posted
• A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural MesotheliomaTerminatedNCT03075527Phase 2Results posted
• Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)Active, not recruitingNCT03043872Phase 3Results posted

← Durvalumab overview